"Macugen (pegaptanib) je modifikovan\u00FD oligonukleotid, kter\u00FD se specificky v\u00E1\u017Ee na extracelul\u00E1rn\u00ED VEGF165, a inaktivuje jej. Inhibuje t\u00EDm procesy vzniku a progrese subretin\u00E1ln\u00ED neogeneze. Selektivn\u00ED inhibice izofomy VEGF165 nevede na rozd\u00EDl od neselektivn\u00ED inhibice, k po\u0161kozen\u00ED fyziologick\u00E9 c\u00E9vn\u00ED struktury c\u00E9vnatky." . "First experience with Macugen therapy in wet AMD"@en . . "445841" . "14110" . . . . . "Kol\u00E1\u0159, Petr" . . . "N" . "RIV/00216224:14110/07:00044529" . "RIV/00216224:14110/07:00044529!RIV11-MSM-14110___" . . "Macugen (pegaptanib) is a modified oligonucleotide that specifically binds to the extracellular VEGF165, and inactivates it. Inhibits the processes of formation and progression of subretinal neovascularization. Selective inhibition of VEGF165 does not lead unlike non selective inhibition, to damage of the physiological vascular structure of the choroid."@en . "1"^^ . . "Prvn\u00ED zku\u0161enosti s terapi\u00ED Macugenem u vlhk\u00E9 formy VPMD" . "Prvn\u00ED zku\u0161enosti s terapi\u00ED Macugenem u vlhk\u00E9 formy VPMD"@cs . . . "Macugen (pegaptanib) je modifikovan\u00FD oligonukleotid, kter\u00FD se specificky v\u00E1\u017Ee na extracelul\u00E1rn\u00ED VEGF165, a inaktivuje jej. Inhibuje t\u00EDm procesy vzniku a progrese subretin\u00E1ln\u00ED neogeneze. Selektivn\u00ED inhibice izofomy VEGF165 nevede na rozd\u00EDl od neselektivn\u00ED inhibice, k po\u0161kozen\u00ED fyziologick\u00E9 c\u00E9vn\u00ED struktury c\u00E9vnatky."@cs . "1"^^ . "Prvn\u00ED zku\u0161enosti s terapi\u00ED Macugenem u vlhk\u00E9 formy VPMD"@cs . . "age related macular degeneration; choroidal neovascular membrane; vascular endothelial growth factor; pegaptanib"@en . "First experience with Macugen therapy in wet AMD"@en . . "[4F7B9292E9C1]" . . "Prvn\u00ED zku\u0161enosti s terapi\u00ED Macugenem u vlhk\u00E9 formy VPMD" . .